Dishman Carbogen Amcis reports strong performance, corrects investor presentation

Dishman Carbogen Amcis Limited submitted a revised investor presentation, correcting typographical/formatting errors on Slides 20 and 23 of an earlier submission. The company reported LTM Q1FY26 revenue of INR 28,958 m with a 20.1% EBITDA margin and a 9.1% FY21-25 revenue CAGR. The FY26 order book stands at INR 23,094 m. The company demonstrates strong returns with an LTM Q1FY26 ROCE of 9.5% and ROE of 6.3%.

Dishman Carbogen Amcis boasts 10 sites across India, Switzerland, UK, France, Netherlands, and China, with 2,200 employees, including 950 scientific staff, 50% holding Ph.D.s. Key capabilities include highly potent API manufacturing, ADC & Bioconjugation, and continuous flow chemistry. For FY25, the overall business reported INR 27,115 m revenue, with the CDMO business (excluding France and Netherlands) contributing INR 20,243 m, an EBIT of INR 2,977 m, and a Return on Capital Employed of 25.1%.